USE OF IL-13 ANTAGONISTS FOR THE TREATMENT OF ATOPIC DERMATITIS Russian patent published in 2021 - IPC A61K39/395 A61P17/00 A61P37/08 

FIELD: medicine.

SUBSTANCE: group of inventions relates to the field of medicine, namely to dermatology and immunology, and is intended for the treatment of atopic dermatitis in a patient. For the treatment of atopic dermatitis in a patient, a pharmaceutical composition containing 125 mg, or 250 mg, or 500 mg of anti-IL-13 antibodies is administered to the patient. The pharmaceutical composition reduces the severity of the disease in the patient, which is evaluated according to the criterion for assessing the severity of the disease for atopic dermatitis (Atopic Dermatitis Disease Severity Outcome Measure). The anti-IL-13 antibody is an antibody containing VH containing HVRH1, HVR-H2, and HVR-H3, wherein the corresponding VH HVRs have the amino acid sequence SEQ ID NO: 5, SEQ ID NO: 6, and SEQ ID NO: 7, and containing VL containing HVR-L1, HVR-L2, and HVR-L3, wherein the corresponding VL HVRs have the amino acid sequence SEQ ID NO: 8, SEQ ID NO: 9 and SEQ ID NO: 10. In another embodiment, 125 mg or 250 mg of anti-IL-13 antibody is administered to the patient subcutaneously once every four weeks or once every eight weeks. A treatment method is also presented that includes the administration of an anti-IL-13 antibody in one shock dose, which is 250 mg or 500 mg, and one subsequent maintenance dose, which is 125 mg or 250 mg, with each of the shock dose and maintenance dose being administered subcutaneously as a constant dose.

EFFECT: use of the group of inventions can reduce the severity of symptoms of atopic dermatitis and maximize the effectiveness of treatment.

76 cl, 12 dwg, 9 tbl, 4 ex